Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:MTSR 30 October 2025 - 21 November 2025

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its $10 billion acquisition of Metsera, paying $65.60 per share plus a contingent value right of up to $20.65 per share. Metsera shares stopped trading on Nasdaq after November 13. On November 21, Pfizer raised $6 billion through a seven-tranche bond sale to help fund the deal. Metsera is now a Pfizer subsidiary.
21 November 2025
···
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

U.S. stock futures rose Monday as Senate action fueled hopes for an end to the government shutdown, with Nvidia up 3% premarket. Pfizer won the $10 billion Metsera bid, sending Novo Nordisk shares higher in Copenhagen. Rumble agreed to buy Germany’s Northern Data in an all-stock deal, gaining access to 22,400 Nvidia GPUs. Tyson Foods raised its FY2026 revenue outlook as chicken sales offset beef weakness.
10 November 2025
····
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera agreed to Pfizer’s revised takeover offer worth up to $10 billion after Novo Nordisk withdrew from bidding. The deal values Metsera at $86.25 per share, including $65.60 in cash and up to $20.65 via a contingent value right. Metsera shareholders will vote on the merger November 13. Both companies expect a swift closing if approved.
8 November 2025
····
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer agreed to acquire Metsera for up to $10 billion, outbidding Novo Nordisk and ending a heated takeover battle. Metsera shareholders will vote on the deal Nov. 13, with closing expected soon after pending approvals. Shares of MTSR surged to $83.18 following the announcement. Regulators are expected to review the deal’s impact on the obesity-drug market.
8 November 2025
·····
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera shares jumped nearly 20% to $73.29 on November 4, 2025, hitting a 52-week high after Novo Nordisk raised its takeover offer to $86.20 per share, topping Pfizer’s $70 bid. Metsera’s board called Novo’s proposal “Superior.” A Delaware judge declined to halt the bidding war, fueling further gains. Pfizer has until midweek to counter Novo’s offer.
4 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo Nordisk made an unsolicited $8.5 billion bid for Metsera, topping Pfizer’s earlier $7.3 billion deal. Metsera’s board called Novo’s offer “superior,” triggering a four-day window for Pfizer to respond. Metsera shares jumped over 18% on the news, while Novo’s stock fell 3%. Pfizer criticized Novo’s move as “reckless,” warning it could suppress competition.
31 October 2025
····
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····

Stock Market Today

  • Thomson Reuters (TRI) Upgraded to Buy on Rising Earnings Estimates
    April 9, 2026, 2:13 PM EDT. Thomson Reuters (TRI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, a key factor influencing stock price movements. The Zacks rating, based solely on changes in earnings potential, signals an improved business outlook. This upgrade reflects growing confidence among institutional investors, who adjust share valuations based on earnings revisions, leading to potential stock price gains. The company is expected to earn $4.40 per share for the fiscal year ending December 2026, in line with last year. This upgrade highlights the importance of tracking earnings estimate revisions as a strategy for investment decisions in the near term.

Latest article

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

9 April 2026
Spot gold rose 1.6% to $4,789.67 an ounce by 1:30 p.m. ET Thursday as the U.S. dollar weakened and Treasury yields slipped. U.S. gold futures settled 0.9% higher at $4,818.00. Traders watched a fragile ceasefire between Washington and Tehran and awaited Friday’s U.S. inflation data. March saw gold’s steepest monthly drop since 2008, according to China’s central bank.
Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

9 April 2026
The Dow Jones rose 247.66 points to 48,155.97 by midday Thursday, following a surge linked to signs of Middle East de-escalation and Israeli plans for peace talks with Lebanon. Oil prices fell over $4 a barrel after Netanyahu’s remarks, but remain 40% above pre-conflict levels. Amazon climbed 4.3% on strong AI revenue. Traders now see only a 30% chance of a Fed rate cut by year-end, down from 56%.
US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

9 April 2026
The Dow rose 337 points, or 0.7%, by 1 p.m. Thursday as oil prices retreated after Israel announced direct talks with Lebanon and hopes for a U.S.-Iran ceasefire steadied markets. Amazon shares climbed on news its AWS AI services topped $15 billion in annualized revenue. The Fed signaled possible rate hikes if inflation persists. Oil shipments through the Strait of Hormuz remained sharply reduced.
Amazon Stock Rises After Andy Jassy Reveals AWS AI Revenue, Defends $200 Billion Spend

Amazon Stock Rises After Andy Jassy Reveals AWS AI Revenue, Defends $200 Billion Spend

9 April 2026
Amazon shares rose 5% Thursday after CEO Andy Jassy revealed AWS’s AI services are generating over $15 billion annually and its chip business more than $20 billion. Jassy said much of AWS’s $200 billion in planned 2026 spending is backed by customer commitments, including a $100 billion OpenAI deal. He also highlighted deep job cuts and a push for smaller teams. Amazon now operates over 1 million robots and plans to launch its Leo satellite network in mid-2026.
Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

9 April 2026
Unilever said Thursday it will acquire U.S. greens-supplement brand Grüns for an undisclosed sum, with the deal expected to close later this year pending approvals. Grüns was valued at about $500 million in a 2025 Series B round, according to Reuters. The purchase follows Unilever’s recent agreement to combine its food business with McCormick.
Go toTop